"Albert M. Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is appointed," the Swiss contract drug manufacturer said.
Lonza said the company's medium-term strategy and outlook would be discussed in detail at the upcoming Capital Markets Day on Oct. 17 in the Swiss city of Visp.
(Reporting by Noele Illien, Editing by Rachel More)
